Key result
TNFα stimulation markedly increases thrombogenicity and thrombin generation in ECFCs compared to unstimulated controls.
Why the study?
Assessing endothelial dysfunction to guide cardiovascular disease management is hindered by limited availability of patient-specific primary endothelial cells.
Does in vitro TNFα activation of donor-derived endothelial colony-forming cells (ECFCs) increase platelet deposition, fibrin formation, and thrombin generation compared to unstimulated ECFCs in modified thrombogenesis and thrombin generation assays?
Does in vitro TNFα activation of donor-derived endothelial colony-forming cells (ECFCs) increase platelet deposition, fibrin formation, and thrombin generation compared to unstimulated ECFCs in modified thrombogenesis and thrombin generation assays?
Combining patient-derived ECFC-modified thrombogenesis and thrombin generation assays provides a viable non-invasive in vitro platform for personalized global assessment of endothelial dysfunction and prothrombotic risk.
Answers are grounded in this paper and cite their sources.
Validates ECFC-based assays for detecting TNFα-driven prothrombotic activity in vitro; leaves open clinical translation for personalized endothelial risk assessment.
The study of endothelial dysfunction (ED) is crucial to identify the pathogenetic mechanism(s) and provide indications for patient management in cardiovascular diseases. It is currently hindered by the limited availability of patient-specific primary endothelial cells (ECs). Endothelial colony-forming cells (ECFCs) represent an optimal non-invasive tool to overcome this issue. Therefore, we investigated the use of ECFCs as a substrate in thrombogenesis and thrombin generation assay (TGA) to assess ED. Both assays were set up on human umbilical vein endothelial cells (HUVECs) and then tested on ECFCs obtained from healthy donors. To prove the ability of the assays to detect endothelial activation, ECs stimulated with TNFα were compared with unstimulated ECs. EC activation was confirmed by the upregulation of VCAM-1 and Tissue Factor expression. Both assays discriminated between unstimulated and activated HUVECs and ECFCs, as significantly higher platelet deposition and fibrin formation in thrombogenesis assay, and thrombin generation in TGA, were observed when TNFα-activated ECs were used as a substrate. The amount of fibrin and thrombin measured in the two assays were directly correlated. Our results support the combined use of a thrombogenesis assay and TGA performed on patient-derived ECFCs to provide a personalized global assessment of ED relevant to the patient's hemostatic profile.
No takes yet. Share an insight, caveat, or question.
Bacci et al. (2023) studied Endothelial dysfunction in cardiovascular diseases (in vitro model using healthy donor ECFCs) (n=9). In vitro TNFα stimulation of endothelial colony-forming cells (ECFCs) and HUVECs vs. Unstimulated ECFCs and HUVECs cultured in basal conditions was evaluated on Platelet deposition, fibrin formation in thrombogenesis assay, and endogenous thrombin potential (ETP) in thrombin generation assay (TGA) on ECFCs (p=<0.01). TNFα-stimulated ECFCs increased platelet deposition, fibrin formation, and thrombin generation compared to unstimulated ECFCs.
Synapse has enriched 10 related papers. Consider them for comparative context: